Colorcon chooses the Netherlands for new starch manufacturing plant

12 Jul 2019

The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

Colorcon is to build a new starch manufacturing plant close to Amsterdam in The Netherlands. By 2022, this new facility is planned to double the existing manufacturing capacity for Starch 1500, Pregelatinized Maize Starch, supporting the continued growth of Colorcon’s excipient business across the world.

Colorcon chooses the Netherlands for new starch manufacturing plant

Strategically located in the heart of Europe and close to the major port of Rotterdam, the site will produce GMP starch products for the pharmaceutical and nutritional markets served by Colorcon in the EMEA region.

Nathan Evans, Operations Project Manager – Netherlands says: “The location has been chosen to bring manufacturing closer to our customer base in Europe. The plant will provide a secure second source of supply with the same quality, consistency and equivalency to the product manufactured in our existing facility in Indianapolis, IN, USA. The new facility will enable Colorcon to take advantage of new advances in process control and automation to manufacture a product that has over 40 years of history in use across the pharmaceutical industry.”

Martti Hedman, CEO, Colorcon explains the significance of Colorcon’s investment: “By investing ahead of demand, the facility is also an important step in securing the supply chain for our customers and enhances Colorcon’s Business Continuity Plan as the demand for Starch 1500 continues to grow.”

Jayesh Parmar, General Manager adds: “Colorcon is committed to providing the highest quality products and superior service to meet our customers’ needs around the world. This investment reinforces our dedication to providing continuity of supply and highlights our long-term commitment to the specialty excipient business.”

Read More

Related categories

Related tags

Market News

Related news

CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
Catalent completes purchase of biologics fill-finish and oral solid dose facility

Catalent completes purchase of biologics fill-finish and oral solid dose facility

7 Jan 2020

Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.

Read more 
Boxing clever: Smart packs improving communication with patients

Boxing clever: Smart packs improving communication with patients

6 Jan 2020

Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.

Read more 
WuXi STA opens large-scale oligonucleotide manufacturing facility

WuXi STA opens large-scale oligonucleotide manufacturing facility

6 Jan 2020

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
UCB to build new biotech manufacturing plant in Belgium

UCB to build new biotech manufacturing plant in Belgium

31 Dec 2019

Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

27 Dec 2019

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.

Read more